64.13 0.00 (0.00%)
Pre-Market: 4:33AM EDT
|Bid||63.72 x 2200|
|Ask||64.07 x 2900|
|Day's Range||63.68 - 64.25|
|52 Week Range||60.32 - 79.61|
|Beta (3Y Monthly)||1.17|
|PE Ratio (TTM)||13.90|
|Forward Dividend & Yield||2.52 (3.93%)|
|1y Target Est||N/A|
Gilead Sciences, the maker of HIV drug Truvada, is moving to challenge patents held by the US government on the preventive use of the drug, which is known as PrEP, amid criticism it used publicly-funded research to bring the drug to market at too steep a price. In a statement on Wednesday, the drugmaker said it strongly believes that the patents granted to HHS for two prophylactic uses of the drug are not valid. Gilead’s petition to the US Patent and Trademark Office is to request a so-called inter partes review, which re-examines the claims in a patent to determine if they are valid.
Cell therapy pioneer and founder Arie Belldegrun has hatched a plan to find more space in the Bay Area for his portfolio of biotech companies.
Durect Corp (DRRX) reported financial results for their second quarter ending June 30th and provided a pipeline development update. ‣ Gilead, HIV/HBV-SABER licensing agreement: on July 22nd DRRX announced an out-licensing agreement with Gilead Sciences, Inc (GILD) related to their SABER (controlled drug delivery) technology in the development of a long-acting injectable HIV product. The agreement, which will pay DRRX $25M upfront and potentially up to another $145M in development and sales related milestones (in addition to tiered royalties on sales) for the initial injectable HIV product, comes after ~two years’ worth of feasibility related work between the parties.
If you want to invest with a clean conscience, look no further. RBC Capital has just released a report revealing its favorite stocks for sustainable investing. These are stocks that the firm rates Outperform (the equivalent of Buy) according to its traditional fundamental financial analysis - and that score highly on key environmental, social and governance (ESG) factors.ESG spans a wide array of factors, from being environmentally sustainable and protecting consumers to boasting gender diversity in the boardroom and ensuring equal pay for employees, and many more."It is thought that ESG factors can be strong signals for future opportunities as well as potential risks including share price volatility, earnings stability and issues management," write RBC Capital analysts, adding, "incorporating environmental, social and governance factors alongside traditional financial analysis can be additive as indicators of corporate performance."Indeed, a Morningstar study of its ESG indexes released earlier this year showed that sustainable investing pays off. "We found that 41 of the 56 Morningstar's ESG indexes outperformed their non-ESG equivalents (73%) since inception," it says. "... Morningstar ESG indexes tend to select companies that are less volatile and possess stronger competitive advantages and healthier balance sheets than their non-ESG equivalents."Here are five of the best ESG stocks on RBC Capital's "Global ESG Best Ideas List." Each of the stocks not only gets RBC's seal of approval, but sports a Moderate Buy or Strong Buy consensus rating from analysts tracked by TipRanks. SEE ALSO: The Berkshire Hathaway Portfolio: All 47 Buffett Stocks
Gilead Sciences did not apply for exclusivity when it sought US approval for Truvada, a drug that could end the HIV epidemic, to be used as a preventive treatment in 2012, according to a review of federal documents. Activists and legal experts say this lack of exclusivity and the publicly backed patents for the drug mean that Gilead’s effective monopoly in the US is invalid, and that generic alternatives could have been made available sooner. Analysis of the US Food and Drug Administration’s Orange Books, which among other information list drug patents as provided by pharmaceutical groups, shows no exclusivity for Truvada for preventive use, a treatment known as pre-exposure prophylaxis, or PrEP.
The Florida startup has Bay Area investors and is aiming straight at people willing to pay thousands of dollars to beat cancer in the future.
Zacks Industry Outlook Highlights: Gilead Sciences, Regeneron Pharmaceuticals, Amgen, Vertex Pharmaceuticals and Alexion Pharmaceuticals
Thursday's gain felt a little too strong to trust, and sure enough, it didn't last. The S&P 500 fell 0.66% on Friday, leaving it squarely in the middle of equally important support and resistance levels.Source: Shutterstock General Electric (NYSE:GE) was the proverbial problem child. It fell more than 3%, logging its seventh loss in eight sessions as worries about its turnaround resurfaced. Smaller Nektar Therapeutics (NASDAQ:NKTR) posted the decidedly larger loss though, giving up nearly 30% of its value after the company reported a production issue with one of the drugs in a key trial right now.One noteworthy winner … Amgen (NASDAQ:AMGN) rallied 6% on the heels of news it has won a case involving the patent on its Enbrel. There just weren't enough names like Amgen to finish the week on a high note.InvestorPlace - Stock Market News, Stock Advice & Trading Tips * 10 Medical Marijuana Stocks to Cure Your Portfolio As the new trading week kicks off, take a closer look at the stock charts of News Corp (NASDAQ:NWSA), Xilinx (NASDAQ:XLNX) and Gilead Sciences (NASDAQ:GILD). They're all positioned for major moves, with just the right nudge. Gilead Sciences (GILD)For the better part of June and July, Gilead Sciences was working on a break above a couple of different resistance levels. Although they were tough, a move above them could mark the beginning of a prolonged move higher. Unfortunately, before that advance had a chance to fully take hold, it petered out in the latter part of July.It may be too soon to give up on GILD stock just yet though. Last week it found support at a (very) familiar spot, and in the meantime we've moved to within reach of what could prove to be a hugely catalytic technical event. * Click to EnlargeThe support is the floor that lines up all the key lows since the end of 2018, marked in white on both stock charts. Gilead shares pushed up and off that floor last week, ending the pullback. * Thanks to June's big jump following a broad rally effort since March, the purple 50-day moving average line is close to crossing above the white 200-day average … a so-called "golden cross" that may spur more buying. * The weekly chart puts things in perspective. The loss since 2015 has been significant. The same weekly chart shows the stock is also on the verge of breaking above a couple different long-term resistance lines driving that downtrend. One is marked in blue, and the other red, tagging all the key highs going back for years. Xilinx (XLNX)Xilinx shares have been fighting a losing battle since July 24, when a budding rally quickly rolled over and turned into a selloff. Broad concerns about trade with China and specific concerns about its relationship with Huawei up-ended the bullish effort.The selloff initially looked manageable. Although the dip wasn't small, shares hinted as if they would find support where they most needed to (and where they did the last time support was found). Thursday's sharp gain largely solidified the bullish backdrop. Friday's big stumble, however, may have cemented more weakness in place. * 10 Internet Stocks Getting Hammered * Click to EnlargeThe line in the sand is the 200-day moving average, plotted in white on both stock charts. XLNX broke that support in a big way on Friday, logging its lowest close in weeks to end the week. * The volume for the past two weeks is problematic for the bulls too. The selling has been on high volume, and the one good day in the midst of the rout -- Thursday -- was clearly on below average volume. * Last week's selling has also pulled Xilinx to within striking distance of a key Fibonacci retracement line near $102. It may not break it with a straight-line move, but it's still vulnerable to such a breakdown. News Corp (NWSA)It was wholly inspired by its fourth-quarter earnings beat. Nonetheless, News Corp shares demonstrated impressive technical strength on Friday, finding support where it ideally would. The big move carried shares to a huge line in the sand as well, and though it didn't push shares past that line, NWSA stock is perfectly positioned to punch through that mark this week. It may just need to peel back a little bit first to get a good running start. * Click to EnlargeThe line in question is right around $13.77, marked in yellow on both stock charts, near where NWSA peaked on Friday as well as in late June. * The rally, however, ultimately started on Wednesday with a hammer-shaped reversal bar that found technical support at the gray 100-day and white 200-day moving average lines. * It would be easy to overlook in the midst of the volatility, but the purple 50-day moving average line moves above the 200-day moving average last month, pointing to a well-established uptrend.As of this writing, James Brumley did not hold a position in any of the aforementioned securities. You can learn more about James at his site, jamesbrumley.com, or follow him on Twitter, at @jbrumley. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 7 Large-Cap Stocks to Sell Right Now * 7 Stocks Under $7 to Invest in Now * 7 Marijuana Stocks With Critical Levels to Watch The post 3 Big Stock Charts for Monday: Xilinx, News Corp and Gilead Sciences appeared first on InvestorPlace.
Gilead Sciences Inc.'s drug Biktarvy has been approved for the treatment of HIV-1 in China, the company said Friday. The China National Medical Products Administration approved the drug as a treatment for patients with HIV-1 that isn't resistant to the integrase inhibitor class of drugs, emtricitabine or tenofovir. Biktarvy received marketing approval from the U.S. Food and Drug Administration and the European Commission in 2018. "Gilead is pleased that people living with HIV in China will now have our newest HIV treatment innovation as a treatment option," said Diana Brainard, Gilead's senior vice president of HIV and emerging viruses, in a statement. Gilead reported earnings last week that beat analysts' expectations. The company's HIV products continue to be a strong base for the company, with second-quarter HIV drug sales growing to $4 billion from $3.7 billion a year ago. Shares of Gilead have gained 3.6% in the year to date through Thursday, while the S&P 500 has gained 17.2%.
Gilead is one of the biggest biotech companies. But recent news and earnings have been mixed. So, is Gilead stock a buy right now? Read on for a full analysis.
CMS, which runs Medicare - the federal government's health plan for Americans 65 and older - said it will cover the U.S. Food and Drug Administration-approved therapies when provided in healthcare facilities that have programs in place to track patient outcomes. The nationwide decision clears up "a lot of confusion" about coverage and will help patients get access to the novel therapies, known as CAR-T, CMS Administrator Seema Verma said during a conference call with reporters on Wednesday. Both Gilead's Yescarta and Novartis' Kymriah were approved in 2017 for certain kinds of lymphoma and leukemia.
The U.S. Centers for Medicare and Medicaid Services (CMS) on Wednesday said it has finalized a decision to cover expensive cancer cell therapies sold by Gilead Sciences Inc and Novartis AG. CMS, which runs Medicare - the federal government's health plan for Americans 65 and older - said it will cover the U.S. Food and Drug Administration-approved therapies when provided in healthcare facilities that have programs in place to track patient outcomes. The nationwide decision clears up "a lot of confusion" about coverage and will help patients get access to the novel therapies, known as CAR-T, CMS Administrator Seema Verma said during a conference call with reporters on Wednesday.